Literature DB >> 2822085

Cell cycle stage dependent variations in drug-induced topoisomerase II mediated DNA cleavage and cytotoxicity.

E Estey1, R C Adlakha, W N Hittelman, L A Zwelling.   

Abstract

The DNA cleavage produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) in mammalian cells is putatively mediated by topoisomerase II. We found that in synchronized HeLa cells the frequency of such cleavage was 4-15-fold greater in mitosis than in S while the DNA of G1 and G2 cells exhibited an intermediate susceptibility to cleavage. The hypersensitivity of mitotic DNA to m-AMSA-induced cleavage was acquired relatively abruptly in late G2 and was lost similarly abruptly in early G1. The susceptibility of mitotic cells to m-AMSA-induced DNA cleavage was not clearly paralleled by an increase in topoisomerase II activity (decatenation of kinetoplast DNA) in 350 mM NaCl extracts from mitotic cells compared to similar extracts from cells in G1, S, or G2. Furthermore, equal amounts of decatenating activity from cells in mitosis and S produced equal amounts of m-AMSA-induced cleavage of simian virus 40 (SV40) DNA; i.e., the interaction between m-AMSA and extractable enzyme was similar in mitosis and S. The DNA of mitotic cells was also hypersensitive to cleavage by 4'-demethylepipodophyllotoxin 4-(4,6-O-ethylidene-beta-D-glucopyranoside) (etoposide), a drug that produces topoisomerase II mediated DNA cleavage without binding to DNA. Thus, alterations in the drug-chromatin interaction during the cell cycle seem an unlikely explanation for results in whole cells. Cell cycle stage dependent fluctuations in m-AMSA-induced DNA cleavage may result from fluctuations in the structure of chromatin per se that occur during the cell cycle.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2822085     DOI: 10.1021/bi00388a023

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  19 in total

Review 1.  Topoisomerase II: its functions and phosphorylation.

Authors:  S M Gasser; R Walter; Q Dang; M E Cardenas
Journal:  Antonie Van Leeuwenhoek       Date:  1992-08       Impact factor: 2.271

2.  Dissociation of cytotoxicity and DNA cleavage activity induced by topoisomerase II-reactive intercalating agents in hamster-human somatic cell hybrids.

Authors:  B S Glisson; A M Killary; P Merta; W E Ross; J Siciliano; M J Siciliano
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 3.  Topoisomerase II: untangling its contribution at the centromere.

Authors:  Andrew C G Porter; Christine J Farr
Journal:  Chromosome Res       Date:  2004       Impact factor: 5.239

Review 4.  Topoisomerases, new targets in cancer chemotherapy.

Authors:  J G Zijlstra; S de Jong; E G de Vries; N H Mulder
Journal:  Med Oncol Tumor Pharmacother       Date:  1990

5.  Topoisomerase II cleavage of herpes simplex virus type 1 DNA in vivo is replication dependent.

Authors:  S N Ebert; S S Shtrom; M T Muller
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

6.  DNA topoisomerase II sites in the histone H4 gene during the highly synchronous cell cycle of Physarum polycephalum.

Authors:  V Borde; M Duguet
Journal:  Nucleic Acids Res       Date:  1998-05-01       Impact factor: 16.971

7.  Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle.

Authors:  M M Heck; W N Hittelman; W C Earnshaw
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

8.  Cell-cycle-dependent phosphorylation and activity of Chinese-hamster ovary topoisomerase II.

Authors:  D A Burden; L J Goldsmith; D M Sullivan
Journal:  Biochem J       Date:  1993-07-01       Impact factor: 3.857

9.  Potentiation of etoposide-induced cytotoxicity and DNA damage in CCRF-CEM cells by pretreatment with non-cytotoxic concentrations of arabinosyl cytosine.

Authors:  C M Chresta; R Hicks; J A Hartley; R L Souhami
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 10.  Topoisomerase II in multiple drug resistance.

Authors:  G A Hofmann; M R Mattern
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.